Studies have shown that PARP1 inhibition (using olaparib) demonstrates promising antitumor activity in HNSCC cells, particularly in conditions of HR deficiency, radiation-induced stress, and in combination with cetuximab or KDM inhibitors. This evidence concerns the gene PARP1 and head and neck squamous cell carcinoma.